Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 4
2011 1
2017 1
2019 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean chuang i (127 results)?
1-[(5-tert-Butyl-2-hydroxyphenyl)iminomethyl]-2-napthol.
Sun XX, Ma SL, Huang HB, Qi CM. Sun XX, et al. Among authors: qi cm. Acta Crystallogr C. 2007 Feb;63(Pt 2):o87-8. doi: 10.1107/S0108270106051511. Epub 2007 Jan 13. Acta Crystallogr C. 2007. PMID: 17284814 No abstract available.
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q, Zhang J, Zhong H, Yuan Y, Yang L, Zhang Q, Ji D, Gong J, Li J, Yao Z, Qi C, Wang J, Lu L, Shi M, Qian X, Shen L, Li J, Hu X. Zhang Q, et al. Among authors: qi c. Cancer Immunol Immunother. 2023 Aug;72(8):2729-2739. doi: 10.1007/s00262-023-03434-2. Epub 2023 Apr 28. Cancer Immunol Immunother. 2023. PMID: 37115210 Clinical Trial.
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J, Li J, Bai C, Xu N, Zhou Z, Li Z, Zhou C, Jia R, Lu M, Cheng Y, Mao C, Wang W, Cheng K, Su C, Hua Y, Qi C, Li J, Wang W, Li K, Sun Q, Ren Y, Su W. Xu J, et al. Among authors: qi c. Clin Cancer Res. 2019 Jun 15;25(12):3486-3494. doi: 10.1158/1078-0432.CCR-18-2994. Epub 2019 Mar 4. Clin Cancer Res. 2019. PMID: 30833272 Clinical Trial.
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, Wang J, Zhang L, Frigault MM, Morgan S, Yang L, Lickliter JD. Gan HK, et al. Among authors: qi c. Clin Cancer Res. 2019 Aug 15;25(16):4924-4932. doi: 10.1158/1078-0432.CCR-18-1189. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952639 Clinical Trial.
11 results